Topical vs Oral Finasteride: Key Differences
This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.
Verdict
Topical and oral finasteride produce comparable hair regrowth based on the Phase III trial. The principal difference is systemic exposure: topical finasteride suppresses serum DHT by approximately 4-15% vs 65% for oral. This lower systemic exposure is hypothesised to reduce systemic side effects. Oral finasteride is FDA-approved; topical is not. Oral has decades of safety data; topical has a 24-week trial.
Key takeaways
- Hair regrowth efficacy is comparable between topical and oral finasteride in the Phase III trial.
- Systemic DHT suppression differs substantially: 4-15% for topical vs 65% for oral.
- Oral finasteride is FDA-approved (1997); topical is not.
- Sexual side effects were reported less frequently in the topical group in the Phase III trial.
- Evidence maturity differs greatly: oral has decades of data; topical has a 24-week trial.
- Quality of compounded topical finasteride varies between compounding pharmacies.
Efficacy comparison
The Phase III randomised trial by Piraccini et al. (2021) included an oral finasteride 1mg reference arm alongside topical finasteride 0.25% spray and placebo. Both topical and oral finasteride produced statistically significant improvements in hair count vs placebo. The adjusted mean change from baseline in target area hair count was similar between topical and oral groups, with no statistically significant difference between them. This supports the conclusion that the two deliver equivalent hair count benefits. Full context on finasteride is in our hair restoration guide.
DHT suppression
| Form | Serum DHT suppression | Scalp DHT | FDA-approved |
|---|---|---|---|
| Oral 1mg | ~65% | ~64% | Yes (1997) |
| Topical 0.25% spray | ~4-15% | Substantially reduced | No (compounded) |
The lower serum DHT suppression with topical finasteride is a direct consequence of reduced systemic absorption. Topical application concentrates the drug in scalp tissue while limiting the amount that reaches systemic circulation. Scalp tissue DHT reduction is sufficient to produce hair count improvements comparable to oral. The systemic DHT reduction from oral use, while greater, does not appear to translate to greater hair benefit.
Side effects
Oral finasteride causes sexual side effects (reduced libido, erectile dysfunction, ejaculatory disorders) in approximately 1-2% of men in pivotal trials. These are related to systemic DHT suppression. In the Phase III topical trial, the frequency of sexual adverse events was lower in the topical group than the oral group, consistent with the lower systemic DHT impact. However, this was a 24-week trial and may not detect rare or late-onset side effects. No long-term safety comparison exists.
Regulatory and practical differences
Oral finasteride is FDA-approved, meaning it has been through rigorous review for safety, efficacy, and manufacturing quality. Generic versions are widely available at low cost. Topical finasteride is compounded, meaning it is not subject to the same FDA review. Formulation quality, concentration accuracy, and sterility can vary between compounders. It is typically more expensive than generic oral finasteride.
| Study | Patients | Key finding |
|---|---|---|
| Piraccini 2022: topical finasteride Phase III trial | Phase III RCT (n=458) | Hair count improvement comparable between topical and oral. Topical: 4% serum DHT suppression vs 65% oral. Fewer sexual AEs in topical group. |
| Yu 2026: topical finasteride and minoxidil | Safety review | Safety profile data for topical finasteride. |
| 2025 NMA: combination therapies for AGA | Network meta-analysis | Finasteride plus minoxidil combination outperforms either alone. |
What the research cannot tell you
- Long-term (2-5 year) comparative efficacy and safety between topical and oral.
- Whether post-finasteride syndrome incidence differs between topical and oral formulations.
- Efficacy variation between different compounded topical formulations.
- Whether topical finasteride prevents further hair loss as effectively as oral over years of use.